Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02222285 · ClinicalTrials.gov registry record · NA
An Exploratory, Double-Blind, Placebo-Controlled Study of the Medical Food Vayarin in Children With Autism Spectrum Disorder (ASD)
A NA study of Autistic Disorder, sponsored by Enzymotec.
- Completed
- Registry status
- NA
- Development phase
- 56
- Enrollment target
- 2
- Study locations
NCT02222285: Completed NA study of Autistic Disorder, sponsored by Enzymotec.
NCT02222285 is a NA study of Autistic Disorder that has completed, run by Enzymotec. The registered enrollment target is 56 participants, below the 112-participant average among 27 other Autistic Disorder trials with a reported enrollment target (50% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02222285, a NA study of Autistic Disorder, has completed, sponsored by Enzymotec.
- COMPLETED
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary study objective is to evaluate the efficacy of Vayarin\_005 on ASD related symptoms in children.
Primary Outcome
A significant reduction from baseline to endpoint on the Aberrant Behavior Checklist (ABC) compared to patients administered placebo
Conditions Studied
Interventions
- OTHER Placebo
- OTHER Medical Food : Vayarin_005
Study Locations (2)
New Jersey
- Institute of Neurology and Neurosurgery at St. Barnabas - Livingston
New York
- Spectrum Neuroscience and Treatment Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2014-08 |
| Est. Completion | 2017-10 |
| Phase | NA |
What the finished NCT02222285 record still lists
NCT02222285 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 112-participant average among 27 other Autistic Disorder trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Autistic Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02222285 reports a single indexed study location in New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT02222285 about?
NCT02222285 is a clinical study titled "An Exploratory, Double-Blind, Placebo-Controlled Study of the Medical Food Vayarin in Children With Autism Spectrum Disorder (ASD)". The primary study objective is to evaluate the efficacy of Vayarin\_005 on ASD related symptoms in children.
What is the current status of trial NCT02222285?
This trial is currently completed. It is a NA study. The enrollment target is 56 participants. The study started on 2014-08. Estimated completion is 2017-10.
What conditions does trial NCT02222285 study?
This clinical trial studies the following conditions: Autistic Disorder.
What interventions are being tested in trial NCT02222285?
The interventions under investigation include: Placebo (OTHER), Medical Food : Vayarin_005 (OTHER).
Who is sponsoring clinical trial NCT02222285?
This trial is sponsored by Enzymotec, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02222285 being conducted?
This trial has 2 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autistic Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02222285's enrollment target sits among peer trials
56 16th of 27 higher than 12 of 27 other Autistic Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autistic Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Telehealth Parent-Implemented Intervention for Young Children With Autism Spectrum Disorder (ASD)
RECRUITING · NA
-
Randomized Clinical Trial of TUNE In 3.0: A Social/Emotional Program for Adults With Autism Spectrum Disorder
RECRUITING · NA
-
Alpha Auditory Entrainment for Cognitive Enhancement and Sensory Hypersensitivity in Youth With Developmental Disorders
RECRUITING · NA
-
Project AFECT (Autism Family Empowerment Coaching and Training Program)
ACTIVE NOT RECRUITING · NA
-
Confirmatory Efficacy Trial of Cognitive Enhancement Therapy for Adult Autism Spectrum Disorder
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia